Supernus Pharmaceuticals' GAAP net income for three months 2021 was $5.694 million, down 3.7 times from $21.518 million in the previous year. Revenue increased 37.9% to $130.932 million from $94.976 million a year earlier.
Supernus Pharmaceuticals' GAAP net income for three months 2021 was $5.694 million, down 3.7 times from $21.518 million in the previous year. Revenue increased 37.9% to $130.932 million from $94.976 million a year earlier. 
ir.supernus.com
English (US) 